Patients with grade III tumours, ER‐negative status, PR‐negative status, HER2‐positive status, high Ki‐67 (≥ 20%), taxane‐based regimens (T) and complete clinical response (CR) showed higher ApCR rates. The gene discussed is ERBB2; the disease is neoplasm.